Cargando…
Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study
SUMMARY: The Forteo Patient Registry estimated the incidence of osteosarcoma in US patients treated with teriparatide and enrolled in the study between 2009 and 2019. No incident cases of osteosarcoma were identified among patients registered, and the crude incidence rate was 0 (95% confidence inter...
Autores principales: | Gilsenan, A., Harris, D., Reynolds, M., McSorley, D., Midkiff, K., Jackson, L., Muldavin, B., Kellier-Steele, N., Andrews, E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026426/ https://www.ncbi.nlm.nih.gov/pubmed/33151378 http://dx.doi.org/10.1007/s00198-020-05718-0 |
Ejemplares similares
-
The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years
por: Gilsenan, A., et al.
Publicado: (2018) -
Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15‐Year US Postmarketing Surveillance Study
por: Gilsenan, Alicia, et al.
Publicado: (2020) -
Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data
por: Gilsenan, Alicia, et al.
Publicado: (2020) -
The experience of accommodating privacy restrictions during implementation of a large‐scale surveillance study of an osteoporosis medication
por: Midkiff, Kirk D., et al.
Publicado: (2016) -
The US Postmarketing Surveillance Study of Adult Osteosarcoma and Teriparatide: Study Design and Findings From the First 7 Years
por: Andrews, Elizabeth B, et al.
Publicado: (2012)